Last reviewed · How we verify
NCT05877365
Effects of 21-day Purification Program on Healthy Adults
NA trial testing Standard Process 21-Day Purification Program in Healthy in 32 participants. Completed in 15 January 2024.
31 December 2023
Quick facts
| Lead sponsor | Standard Process Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | double |
| Primary purpose | supportive care |
| Enrollment | 32 |
| Start date | 15 June 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 15 January 2024 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Standard Process 21-Day Purification Program
Conditions studied
- Healthy — all drugs for Healthy →
Sponsor
Standard Process Inc.
Who can join
Adults 18 to 65, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a study to assess the impact of Standard Process's 21-Day Purification Program on metabolic health. Participants will be given the opportunity to consume the complex combination of vitamins, minerals, and antioxidants that comprise the 21-Day Guided Purification Program by Standard Process.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Metabolic reset purification program improves antioxidant balance and gut microbiome in individuals transitioning to a healthier diet.
Panda C, Kruse R, Williams K, Nance B, et al · · 2025 · PMID 40860479 · DOI 10.3389/fnut.2025.1621709
Verify or expand the search:
- PubMed search for NCT05877365
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Healthy
Currently open trials in the same condition.
- NCT06707207 — Predicting Future Errors During Skill Performance · recruiting
- NCT07169630 — PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI) · Phase 1 · recruiting
- NCT07499414 — The Effects of the Bile Acid Supplement, 7-keto Lithocholic Acid, on Human Gut Microbiota and Risk Factors for Disease. · NA · recruiting
- NCT07496697 — Effects of Electroacupuncture at NP82 and SP15 on Bowel Motility in Healthy Subjects · NA · recruiting
- NCT06431932 — Pilot Trial of Fisetin in Healthy Volunteers and Older Patients With Multimorbidity · Phase 1, PHASE2 · recruiting
Other Standard Process Inc. trials
Trials by the same sponsor.
- NCT07371598 — Royal Ancient Oats™ Study · NA · recruiting
- NCT07373574 — Effects of Dietary Supplements on Nail and Hair Health · NA · not yet recruiting
- NCT06840574 — The Effect of Nutritional Supplementation on Actinic Purpura: A Pilot Study · NA · suspended
- NCT06795945 — A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate the Safety of a Bovine Thymus Nuclear Extract · NA · completed
- NCT05795946 — Standard Process Heart and Gut Health Study · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05877365 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Standard Process Inc.
- Last refreshed: 14 November 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05877365.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing